Stressnor 0.5 mg
CNS preparations (Anxiolytics, sedatives & hypnotics)
Composition
- Alprazolam 0.5 mg
Dosage form
- Tablets
Therapeutic Indication
- Stressnor is indicated for the short-term treatment of moderate or severe anxiety states and anxiety associated with depression. It is only indicated when the disorder is severe, disabling or subjecting the individual to extreme distress.
- Stressnor should not be used to treat short-term mild anxiety, such as anxiety or tension associated with the stress of everyday life. As the efficacy of Stressnor in depression and in phobic or obsessional states has yet to be established, specific treatment may have to be considered.
Dosage and route of administration
-
Anxiety
250 micrograms (0.25mg) to 500
micrograms (0.5 mg) three times daily, increasing if required to a total of 3 mg daily.
The elderly or in the presence of debilitating disease 250 micrograms (0.25 mg) two to three times daily to be gradually increased if needed and tolerated.
If side-effects occur, the dose should be lowered. It is advisable to review treatment regularly and to discontinue use as soon as possible.
Should longer-term treatment be necessary, then
intermittent treatment may be considered to minimize the risk of dependence.
Paediatric population The safety and efficacy of alprazolam in children and adolescents below the age of 18 years
have not been established. No data are available.
Treatment should be as short as possible. It is recommended that the patient be reassessed at the end of no longer than 4 weeks of treatment and the need for continued treatment established, especially in case the patient is symptom free. The overall duration of treatment should not be more than 8-12 weeks, including a tapering off process.
-
In certain cases extension beyond the maximum treatment period may be necessary; if so, it should not take place without re-evaluation of the patient’s status with special expertise. As with all benzodiazepines, physicians should be aware that long-term use might lead to dependence in certain patients.
The optimum dosage of Stressnor should be based upon the severity of the symptoms and individual patient response. The lowest dose which can control symptoms should be used.
Dosage should be reassessed at intervals of no more than 4 weeks. The usual dosage is stated below; in the few patients who require higher doses, the dosage should be increased cautiously to avoid adverse effects. When higher dosage is required, the evening dose should be increased before the daytime doses. In general, patients who have not previously received psychotropic medications will require lower doses than those so treated, or those with a history of chronic alcoholism.
Package
- Carton box containing 1,2,3 (AL/transparent PVC) strips, each of 10 tablets + inner leaflet
